histiocyte

A histiocyte is a differentiated tissue cell that has its origin in the bone marrow.

Hence, etoposide has not been used in subsequent Histiocyte Society trials.

Some definitions are in order, and reflect the preferred nomenclature of the writing group of the Histiocyte Society.

Clinical trials organized by the Histiocyte Society have been accruing patients on childhood treatment studies since the 1980s.

Histiocytoses describe neoplasias where the proliferative cell is the histiocyte.

The most common histiocyte disorders are Langerhans' cell histiocytosis and haemophagocytic lymphohistiocytosis.

For more information about LCH trials for adults, see the Histiocyte Society website.

However, the term "histiocyte" has been used for multiple purposes in the past, and some cells called "histocytes" don't appear to derive from monocytic-macrophage lines.

Lymphadenopathy of the neck is the most common place of histiocyte accumulation, although accumulation outside of lymph nodes may occur, as well.

The LCH-Malignancy Study Group of the Histiocyte Society.

In sum, there is histiocyte proliferation, and on staining, the section is CD68+ and CD1a-.

A histiocyte is an animal cell that is part of the mononuclear phagocyte system (also known as the reticuloendothelial system or lymphoreticular system).

Sea-blue histiocyte syndrome is seen in patients receiving fat emulsion as a part of long-term parenteral nutrition (TPN) for intestinal failure.

Anichkov first described the specialized myocardial cells (Anitschkow cell, cardiac histiocyte) and discovered the significance and role of cholesterol in atherosclerosis pathogenesis.

The monocyte is formed in the bone marrow and transported by the blood; it migrates into the tissues, where it transforms into a histiocyte or a macrophage.

The disease has gone by several names, including Hand-Schüller-Christian disease, Abt-Letterer-Siwe disease, and histiocytosis X, until it was renamed in 1985 by the Histiocyte Society.

A comprehensive review of the DAL and Histiocyte Society clinical trials revealed a reactivation rate of 46% at 5 years, with most reactivations occurring within two years of first remission.

A special type of Reed-Sternberg cells is the lacunar histiocyte, whose cytoplasm retracts when fixed in formalin, so the nuclei give the appearance of cells that lie with empty spaces (called lacunae) between them.

The current Histiocyte Society clinical trial for patients with refractory high-risk organ (liver, spleen or bone marrow) involvement, as well as resistant multisystem low-risk organ involvement, is an intensive acute myeloid leukemia-like protocol.

Weitzman S, Wayne AS, Arceci R, et al.: Nucleoside analogues in the therapy of Langerhans cell histiocytosis: a survey of members of the histiocyte society and review of the literature.

Haupt R, Nanduri V, Calevo MG, et al.: Permanent consequences in Langerhans cell histiocytosis patients: a pilot study from the Histiocyte Society-Late Effects Study Group.

(The term Histiocyte can also simply refer to a cell from monocyte origin outside the blood system, such as in a tissue (as in rheumatoid arthritis as palisading histiocytes surrounding fibrinoid necrosis of rheumatoid nodules).

The Histiocyte Society, a nonprofit organization, is a group of more than 200 physicians and scientists from around the world committed to improving the lives of patients with histiocytic disorders by conducting clinical and laboratory research into the causes and treatment of this disease.